Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.06 USD | +1.92% | +1.92% | -23.19% |
Apr. 30 | In8bio, Inc. Doses First Patient in Phase 2 Clinical Trial of Inb-400 in Newly Diagnosed Glioblastoma | CI |
Apr. 10 | Top Premarket Gainers | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-23.19% | 45.78M | |
-1.56% | 104B | |
+6.57% | 97.47B | |
+5.71% | 22.25B | |
-12.88% | 21.68B | |
-9.70% | 18.2B | |
-39.98% | 17.02B | |
-9.82% | 16.36B | |
+8.28% | 14.39B | |
+36.50% | 12.37B |
- Stock Market
- Equities
- INAB Stock
- News IN8bio, Inc.
- EF Hutton Initiates IN8bio at Buy With $8 Price Target